Close
4

Seqens Seqens

X

Company profile for Opthea

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
Opthea is committed to improving vision in patients suffering from retinal eye diseases. We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in conjunction with existing standard of care anti-VEGF-A therapies. OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilit...
Opthea is committed to improving vision in patients suffering from retinal eye diseases. We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in conjunction with existing standard of care anti-VEGF-A therapies. OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in Phase 2 wet AMD and DME clinical trials.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Opthea
Australia Flag
Country
Country
Australia
Address
Address
Suite 0403, Level 4, 650 Chapel Street, South Yarra, Victoria 3141
Telephone
Telephone
+613 9826 0399

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY